Positions

Selected Publications

Academic Article

Year Title Altmetric
2022 Omicron variant (B.1.1.529) of SARS-CoV-2, a global urgent public health alert!Journal of Medical Virology.  94:1255-1256. 2022
2021 Epigallocatechin gallate from green tea effectively blocks infection of SARS-CoV-2 and new variants by inhibiting spike binding to ACE2 receptorCell & Bioscience.  11. 2021
2021 Human low-density lipoprotein receptor plays an important role in hepatitis B virus infectionPLoS Pathogens.  17. 2021
2021 An engineered receptor-binding domain improves the immunogenicity of multivalent SARS-CoV-2 vaccinesmBio.  12. 2021
2020 An engineered receptor-binding domain improves the immunogenicity of multivalent SARS-CoV-2 vaccines. 2020
2020 Global health concerns stirred by emerging viral infectionsJournal of Medical Virology.  92:399-400. 2020
2020 Zika virus NS5 nuclear accumulation is protective of protein degradation and is required for viral RNA replicationVirology.  541:124-135. 2020
2019 Functional characterization of apolipoproteins in the HCV life cycleMethods in Molecular Biology.  1911:235-246. 2019
2019 Human apolipoprotein e promotes hepatitis B virus infection and productionPLoS Pathogens.  15. 2019
2018 Tet-inducible production of infectious zika virus from the full-length cdna clones of African-and Asian-lineage strainsViruses.  10. 2018
2018 Characterization of apolipoprotein C1 in hepatitis C virus infection and morphogenesisVirology.  524:1-9. 2018
2018 Robust human and murine hepatocyte culture models of hepatitis B virus infection and replicationJournal of Virology.  92. 2018
2017 Attachment and postattachment receptors important for hepatitis C virus infection and cell-to-cell transmissionJournal of Virology.  91. 2017
2017 Identification of cellular genes and pathways important for tumorigenicity of hepatocellular carcinoma cell lines by proteomic profilingOncotarget.  8:96171-96183. 2017
2017 TIM-1 promotes hepatitis C virus cell attachment and infectionJournal of Virology.  91. 2017
2016 Roles of human apolipoprotein E in the infectivity and replication of hepatitis C virus genotype 2aThe Journal of Microbiology.  54:451-458. 2016
2015 Oncogenic viruses and cancerVirologica Sinica.  30:83-84. 2015
2015 A Dual-Reporter System for Real-Time Monitoring and High-throughput CRISPR/Cas9 Library Screening of the Hepatitis C VirusScientific Reports.  5. 2015
2015 Characterization of hepatitis C virus interaction with heparan sulfate proteoglycansJournal of Virology.  89:3846-3858. 2015
2015 The serum very-low-density lipoprotein serves as a restriction factor against hepatitis C virus infectionJournal of Virology.  89:6782-6791. 2015
2013 Apolipoprotein E Mediates Attachment of Clinical Hepatitis C Virus to Hepatocytes by Binding to Cell Surface Heparan Sulfate Proteoglycan ReceptorsPLoS One.  8. 2013
2013 Syndecan-1 serves as the major receptor for attachment of hepatitis C virus to the surfaces of hepatocytesJournal of Virology.  87:6866-6875. 2013
2013 Ribosomal protein S25 dependency reveals a common mechanism for diverse internal ribosome entry sites and ribosome shuntingMolecular and Cellular Biology.  33:1016-1026. 2013
2013 Modulation of hepatitis C virus RNA abundance and virus release by dispersion of processing bodies and enrichment of stress granulesVirology.  435:472-484. 2013
2013 Hepatitis C virus inhibits AKT-tuberous sclerosis complex (TSC), the mechanistic target of rapamycin (MTOR) pathway, through endoplasmic reticulum stress to induce autophagyAutophagy.  9:175-195. 2013
2012 Transient activation of the PI3K-AKT pathway by hepatitis C virusto enhance viral entryJournal of Biological Chemistry.  287:41922-41930. 2012
2012 cell culture-adaptive mutations promote viral protein-protein interactions and morphogenesis of infectious hepatitis C virusJournal of Virology.  86:8987-8997. 2012
2012 Hepatitis C virus attachment mediated by apolipoprotein E binding to cell surface heparan sulfateJournal of Virology.  86:7256-7267. 2012
2012 Hepatitis C virus infects the endothelial cells of the blood-brain barrierGastroenterology.  142:634-643.e6. 2012
2011 Recent advance in antiviral drugs for hepatitis CZhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences.  36:1025-1036. 2011
2010 Inhibition of hepatitis C virus replication using adeno-associated virus vector delivery of an exogenous anti-hepatitis C virus microrna clusterHepatology.  52:1877-1887. 2010
2010 Hepatitis c virus core-derived peptides inhibit genotype 1b viral genome replication via interaction with DDX3XPLoS One.  5:1-10. 2010
2010 The C-terminal α-helix domain of apolipoprotein E is required for interaction with nonstructural protein 5A and assembly of hepatitis C virusJournal of Virology.  84:11532-11541. 2010
2010 Apolipoprotein E but not B is required for the formation of infectious hepatitis C virus particles (Journal of Virology (2009) 83, 24 (12680-12691))Journal of Virology.  84:4864. 2010
2010 Apolipoprotein E interacts with hepatitis C virus nonstructural protein 5A and determines assembly of infectious particlesHepatology.  51:43-53. 2010
2009 Apolipoprotein E but not B is required for the formation of infectious hepatitis C virus particlesJournal of Virology.  83:12680-12691. 2009
2009 FGI-104: A broad-spectrum small molecule inhibitor of viral infectionAmerican Journal of Translational Research.  1:87-98. 2009
2009 Proteomics study of the hepatitis C virus replication complex.Methods in Molecular Biology.  510:185-193. 2009
2008 Fatty acid synthase is up-regulated during hepatitis C virus infection and regulates hepatitis C virus entry and productionHepatology.  48:1396-1403. 2008
2008 Centrifugal enhancement of hepatitis C virus infection of human hepatocytesJournal of Virological Methods.  148:161-165. 2008
2007 Human apolipoprotein E is required for infectivity and production of hepatitis C virus in cell cultureJournal of Virology.  81:13783-13793. 2007
2007 Human serum amyloid A protein inhibits hepatitis C virus entry into cellsJournal of Virology.  81:6128-6133. 2007
2007 Immunogenic and functional organization of hepatitis C virus (HCV) glycoprotein E2 on infectious HCV virionsJournal of Virology.  81:1043-1047. 2007
2006 Replication of hepatitis C virus (HCV) RNA in mouse embryonic fibroblasts: Protein kinase R (PKR)-dependent and PKR-independent mechanisms for controlling HCV RNA replication and mediating interferon activitiesJournal of Virology.  80:7364-7374. 2006
2006 The polypyrimidine tract-binding protein (PTB) is required for efficient replication of hepatitis C virus (HCV) RNAVirus Research.  115:1-8. 2006
2005 Robust production of infectious hepatitis C virus (HCV) from stably HCV cDNA-transfected human hepatoma cellsJournal of Virology.  79:13963-13973. 2005
2005 Heterologous RNA replication enhancer stimulates in vitro RNA synthesis and template-switching by the carmovirus, but not by the tombusvirus, RNA-dependent RNA polymerase: Implication for modular evolution of RNA virusesVirology.  341:107-121. 2005
2005 Mutagenesis analysis of the rGTP-specific binding site of hepatitis C virus RNA-dependent RNA polymeraseJournal of Virology.  79:11607-11617. 2005
2005 Stimulation of hepatitis C virus (HCV) nonstructural protein 3 (NS3) helicase activity by the NS3 protease domain and by HCV RNA-dependent RNA polymeraseJournal of Virology.  79:8687-8697. 2005
2005 An in vitro model of hepatitis C virion productionProceedings of the National Academy of Sciences of USA.  102:2579-2583. 2005
2004 Kinetics of severe acute respiratory syndrome (SARS) coronavirus-specific antibodies in 271 laboratory-confirmed cases of SARSClinical and Vaccine Immunology.  11:792-794. 2004
2004 Effects of Mutations of the Initiation Nucleotides on Hepatitis C Virus RNA Replication in the CellJournal of Virology.  78:3633-3643. 2004
2004 Orally Active Fusion Inhibitor of Respiratory Syncytial VirusAntimicrobial Agents and Chemotherapy.  48:413-422. 2004
2003 Heterocyclic aminopyrrolidine derivatives as melatoninergic agents.Bioorganic and Medicinal Chemistry Letters.  13:4381-4384. 2003
2003 Replication of hepatitis C virus RNA occurs in a membrane-bound replication complex containing nonstructural viral proteins and RNAJournal of General Virology.  84:2761-2769. 2003
2003 Role of the 5′-proximal stem-loop structure of the 5′ untranslated region in replication and translation of hepatitis C virus RNAJournal of Virology.  77:3312-3318. 2003
2003 Retrospective analysis of non-A-E hepatitis: Possible role of hepatitis B and C virus infectionJournal of Medical Virology.  69:59-65. 2003
2002 Structure-activity relationships for a series of thiobenzamide influenza fusion inhibitors derived from 1,3,3-trimethyl-5-hydroxy-cyclohexylmethylamineBioorganic and Medicinal Chemistry Letters.  12:3379-3382. 2002
2001 An approach to the identification of potent inhibitors of influenza virus fusion using parallel synthesis methodologyBioorganic and Medicinal Chemistry Letters.  11:2393-2396. 2001
2000 Salicylamide inhibitors of influenza virus fusionBioorganic and Medicinal Chemistry Letters.  10:1649-1652. 2000
2000 De novo initiation of RNA synthesis by the RNA-dependent RNA polymerase (NS5B) of hepatitis C virusJournal of Virology.  74:851-863. 2000
1999 Novel quinolizidine salicylamide influenza fusion inhibitorsBioorganic and Medicinal Chemistry Letters.  9:2177-2180. 1999
1999 Conquering influenza: Recent advances in anti-influenza drug discoveryIDrugs: the Investigational Drugs Journal.  2:671-685. 1999
1999 Cellular proteins bind to the poly(U) tract of the 3' untranslated region of hepatitis C virus RNA genomeVirology.  256:105-118. 1999
1999 pH-dependent changes in photoaffinity labeling patterns of the H1 influenza virus hemagglutinin by using an inhibitor of viral fusionJournal of Virology.  73:1785-1794. 1999
1997 Inhibition of influenza viral polymerases by minimal viral RNA decoysJournal of General Virology.  78:2329-2333. 1997
1997 Molecular mechanism underlying the action of a novel fusion inhibitor of influenza A virusJournal of Virology.  71:4062-4070. 1997
1996 Characterization of a hemagglutinin-specific inhibitor of influenza A virusVirology.  226:66-76. 1996
1996 Characterization of inhibition of M2 ion channel activity by BL-1743, an inhibitor of influenza A virusJournal of Virology.  70:4246-4252. 1996
1995 Growth impairment resulting from expression of influenza virus M2 protein in Saccharomyces cerevisiae: Identification of a novel inhibitor of influenza virusAntimicrobial Agents and Chemotherapy.  39:2204-2209. 1995
1994 Mutations at palmitylation sites of the influenza virus hemagglutinin affect virus formationJournal of Virology.  68:5748-5754. 1994
1993 Erratum: Alterations of the stalk of the influenza virus neuraminidase: Deletions and insertions (Virus Research, 29/2, pp. 141-153 (1993))Virus Research.  29:321. 1993
1992 Genetic analysis of influenza virusCurrent Opinion in Genetics and Development.  2:77-81. 1992
1992 Mechanism of attenuation of a chimeric influenza A/B transfectant virusJournal of Virology.  66:4679-4685. 1992
1991 The polyadenylation signal of influenza virus RNA involves a stretch of uridines followed by the RNA duplex of the panhandle structureJournal of Virology.  65:2861-2867. 1991
1990 A specific base transition occurs on replicating hepatitis delta virus RNAJournal of Virology.  64:1021-1027. 1990
1990 Specificities involved in the initiation of retroviral plus-strand DNAJournal of Virology.  64:592-597. 1990
1990 Template switching by reverse transcriptase during DNA synthesisJournal of Virology.  64:4321-4328. 1990

Education And Training

  • Master of Public Health, Capital Medical University 1986
  • Doctorate in Medicine, Central South University 1983
  • Full Name

  • Guangxiang Luo